The price and efficacy of adagrasib: how to evaluate the cost-effectiveness

Evaluating the cost-effectiveness of Adagrasib (Adagrasib) is a complex issue that requires comprehensive consideration of multiple factors. Adagarasib was shown to be beneficial in patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutations and had an acceptable safety profile. Although the main study did not compare adagrasib to another cancer treatment, studies have shown that the drug is effective in treating cancer, including in patients whose disease has worsened after several different treatments.

In addition to considering the efficacy itself, the duration of the treatment effect should also be considered. Adagrasiib was able to provide longer-term stabilization or relief of symptoms. In the study, 41.4% of patients (48 of 116) had a partial or complete response (measured by reduction in cancer size) to adagrasiib treatment, with responses lasting an average of 8.5 months. Therefore, its cost-effectiveness will be higher than other treatments for patients with non-small cell lung cancer. Common side effects include diarrhea, nausea, vomiting, fatigue, decreased appetite, peripheral edema (especially swelling of ankles and feet), and dizziness. Doctors may adjust the dosage of the drug based on the patient's side effects to reduce their symptoms.

The price of adagrasib is also one of the important factors in evaluating the cost-effectiveness. The price of a drug may vary depending on factors such as supplier, region and market competition. The original adagrasibu drug sold overseas, 200mg*180 tablets per box, is priced at more than 100,000 RMB (the price may fluctuate due to the exchange rate), while the latest first generic drug, 200mg*90 tablets per box, is only over 4,000 RMB (the price may fluctuate due to the exchange rate), and the ingredients of the two drugs are basically the same, which is much cheaper than the original drug.